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The 2017 Stanley A. Plotkin Lecture in Vaccinology was delivered by Professor Peter F. Wright at the Pediatric 
Academic Societies Annual Meeting in San Francisco, California, USA, in May of 2017.  The presentation provided 
an overview of the mucosal immune system as it applies to vaccinology.  Specifically, Professor Wright’s lecture 
highlighted the remarkable opportunities for mucosal immunity research afforded by having both topically 
administered live vaccines and systemically administered inactivated vaccines available for the same pathogen.  
Using the case studies of influenza and poliovirus, Professor Wright described the use of live, attenuated vaccines 
for human challenges and discussed how recent technological advancements in immunological assays have ushered 
in a new era for investigating the correlates of immune protection against wildtype infections at mucosal sites.   
The mucosal immune system is highly complex and heterogeneous in its structure and function across the 
body’s mucous membranes.  Variability in mucosal environments can be observed in terms of:  protective 
defense mechanisms (e.g., diarrhea, sneezing, and coughing), microbial colonization patterns (e.g., vaginal 
mucosae are predominately populated by Lactobacilli species while the uterine mucosae remain relatively 
sterile), and relative concentrations of immunoglobulin (Ig) isotypes (e.g., the ratio of IgA to IgG is greater 
than 400:1 in the parotid saliva and less than 1:1 in cervical secretions).  However, common to all mucosal 
tissue substrates is the key role of the mucosal immune system in protecting the body from microbial 
pathogens.  Indeed, in many cases, the immune mediators at mucosal sites serve as the body’s first line of 
defense against infection.  In addition to its function in protecting individuals from disease, mucosal 
immunity is also essential for preserving population health.  For pathogens that replicate in mucosal tissues 
(e.g., influenza [1], respiratory syncytial virus [2], and poliovirus [3]), a robust mucosal response is capable 
of rapidly controlling microbial shedding and, thereby, interrupting the onward transmission of the 
infectious agents to susceptible individuals.   
Despite its clinical significance, conventional study of mucosal immunity has been limited due to a 
combination of technological and biological constraints.  Sample collection can be invasive (e.g., mucosal 
biopsies during endoscopies), specimen storage can be challenging (e.g., proteolytic enzymes may degrade 
antibodies), and immunoassays can be labor-intensive to perform and may have limited sensitivity to detect 
clinically meaningful differences.  Vaccine “challenge” studies have allowed us to overcome some of these 
limitations.  For these clinical trials, individuals (who may be immune-naïve or randomized to receive a 
specific primary vaccine schedule) are administered a challenge dose of a live vaccine as a proxy for natural 
exposure to the pathogen.  During subsequent follow-up visits, a longitudinal series of mucosal samples 
are collected, and the amount of vaccine-derived virus recovered from the samples is quantified.  The 
presence/absence of a given virus or the titer of viral shedding provide surrogate indicators of mucosal 
immune protection.  In our own practice, this research has demonstrated that vaccine-derived live virus 
is less likely to be recovered, after challenge with a live attenuated influenza vaccine (LAIV), in nasal washes 
from children primed with LAIV than in children primed with inactivated influenza vaccine [4].  Similarly, 
this approach has shown that lower titers of poliovirus type 2, after challenge with a type 2 oral polio 
vaccine (OPV), are recovered in stool collected from children immunized with trivalent OPV than bivalent 
OPV (types 1 and 3) with or without a supplementary dose of trivalent inactivated polio vaccine [5]. 
Today, recent advances in biotechnology have enabled us, in a convincing way, to identify immune 
parameters that are associated with the induction of mucosal immunity and that provide protection from 
viral replication at mucosal sites on challenge with a live vaccine.  Specifically, the development of 
luciferase-expressing pseudoviruses (e.g., polio pseudoviruses [6]) have made it possible to quantify 
antibody function in its ability to neutralize virus present in mucosal samples.  As this pseudovirus assay 
measures a single cycle of virus growth, it facilitates rapid turnaround, reduces contamination risks, and is 
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associated with fewer cellular toxicity issues.  Equally important have been multiplex bead-based assays 
utilizing Luminex® (Austin, Texas, USA) that can quantify the concentrations of several, serotype-specific 
binding antibodies in a single assay [7].   A prime example of these technologies in action has been our 
recent investigations into vaccine-induced mucosal immunity to poliovirus.  Utilizing these assays in the 
study of infant stool samples, we have observed:  (i) a brisk mucosal response to live OPV challenge that 
closely tracks the temporal kinetics of viral shedding, (ii) significant pairwise correlations between 
serotype-specific IgA concentration, pseudovirus neutralizing activity, and diminution of viral shedding, and 
(iii) a notable lack of correlation between mucosal responses and a child’s pre-challenge serum immunity 
[5, 7].  In our on-going investigations, we are comparing the induction of mucosal immunity between 
varying infant polio vaccine schedules, using fecal samples collected from a series of clinical trials conducted 
under the auspices of the Bill and Melinda Gates Foundation.  If robust correlations continue to be 
established between poliovirus shedding and pseudovirus neutralizing activity and polio type-specific 
immunoglobulin concentrations in stool samples, then it is plausible that we could examine the primary 
mucosal immunogenicity of vaccines in the absence of a live vaccine challenge.  This could be of exceptional 
value for evaluating individuals’ mucosal responses, in real time, to emerging vaccines like the ‘new’ oral 
polio vaccines (nOPVs), which are a class of highly attenuated and stable live vaccines designed to have 
reduced risks of reversion to neurovirulence and capacity for transmission relative to conventional OPVs 
[8].   
Looking to the future, much remains to be learned about the mucosal immune system and its significance 
for vaccines.  Some specific questions that warrant further investigation include: 
 What is the duration of vaccine-induced mucosal immune protection?   
 Can mucosal antibodies be primed via natural exposure or immunization with live vaccines, such 
that mucosal responses can be generated upon subsequent exposure to inactivated vaccines? 
 How broadly does mucosal protection reach beyond the epithelial cell layer? Can mucosal 
immunity influence replication of viruses (e.g., HIV and poliovirus) in perimucosal sites?   
 Which biological features underlie the observed variability in the mucosal immune responses to 
specific vaccines?   
 Why does viral replication appear to be necessary for the induction of mucosal immunity against 
certain pathogens?   
 How do we explain the effectiveness of selected inactivated vaccines, such as those against human 
papillomavirus and cholera toxins, in conferring mucosal protection?   
 To what degree do neutralizing antibodies in the serum transudate to mucosal surfaces?  Does 
boosting the neutralizing response in the serum have ancillary benefits for mucosal immunity?   
 Are there adjuvants capable of enhancing the mucosal immunogenicity of vaccines?  
 Can the aforementioned pseudovirus neutralization approaches and highly targeted bead-based 
immunoassays be adapted for investigations of other mucosally replicating pathogens? Can the 
platforms be utilized with other biological matrices (e.g., cervical secretions, breast milk, and 
parotid saliva)?      
In conclusion, mucosal immunity has, for too long, been the forgotten arm of the immune system. A 
combination of highly effective mucosally delivered vaccines, vaccine challenge studies to define mucosal 
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immunity and new assays with high specificity and the capacity to measure functional immune responses 
are now unraveling the long suspected role of mucosal immunity in our immune armamentarium.   
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